A rendering of Bayer's consumer health products supply center in Qidong, Nantong. [Photo/WeChat account:qidongfabu]

The construction of Bayer's new consumer health products supply center in Qidong Economic Development Zone is progressing steadily. With a planned investment of 750 million yuan ($102.61 million), the project will feature a modern, multifunctional supply center including solid dosage production workshops, laboratories, warehouses, and utility facilities.  Once completed, it is expected to produce 1.4 billion oral solid dosage tablets annually. If construction advances smoothly, the new facility is set to be completed in early 2026 and officially put into operation by 2028.

Bayer, a Fortune Global 500 company headquartered in Germany, established its presence in Qidong as early as 2008. The Bayer Healthcare Qidong Branch has since been engaged in the production of oral solid and liquid pharmaceutical products.

"We have maintained a strong partnership with the Qidong government over the years," said Qi Wenming, head of Bayer's user team. He noted that in recent years, Qidong has continued to optimize its business environment, especially by streamlining approvals for major projects. Enjoying these policy benefits, Bayer decided to integrate its regional resources and invest in building the supply center.

"China is the second-largest market globally for Bayer's consumer health products," Qi added. The new supply center project will further strengthen Bayer's strategic footprint in China and enhance its global supply chain. The first phase of the project will take over the production tasks of the existing Qidong plant, and in the future, products for export to Europe and other regions are expected to be produced at the new facility.